Professor Gerry McElvaney is the Chairman of the Department of Medicine and Vice Dean of the Medical School at the Royal College of Surgeons in Ireland. His research integrates material science and biological paradigms in developing solutions for chronic disease.
Prof. McElvaney has a well-established track record in research into Cystic Fibrosis alpha -1 antitrypsin deficiency and his work on inflammation and lung defences has led to interactions with pharmaceutical companies interested in translational research. This synergy has led to clinical trials for emerging therapeutics for cystic fibrosis and alpha-1 antitrypsin deficiency. In 2003 he founded the Alpha One Foundation of Ireland and subsequently received funding from the Department of Health and Children to set up an Alpha One Research unit to further research into Alpha-1 antitrypsin deficiency. He also established the first targeted detection programme and Registry for individuals with Alpha-1 antitrypsin deficiency in Europe.
Prof. McElvaney has a strong track record in translational research and has published widely in the areas of Cystic Fibrosis, hereditary emphysema and lung inflammation.
Prof. McElvaney was inducted as a Fellow of Royal College of Physicians of Canada (Pulmonary Medicine and Internal Medicine) and is a member of the Royal College of Physicians of Ireland. He is the President of the Irish Academy of Medical Science.
Prof. McElvaney has published more than 220 papers in peer-reviewed journals and holds one patent. He was elected Member of the US Alpha one TAP Committee to facilitate academia–industrial interactions to cure AATD. He is on the board of the Alpha One Foundation (USA)
Prof. McElvaney is a reviewer for 16 journals and serves on seven grant panels.
Links to published papers on PubMed
+353 (0) 91 495833